VIRTUOZZO
3.6.2021 12:32:08 CEST | Business Wire | Press release
Virtuozzo , a global leader in high-efficiency virtualization and hyperconverged software solutions, has welcomed Mick Bradley as its new Vice President of Global Sales. Mick joins Virtuozzo with over 25 years of sales leadership and management experience in the IT/Software industry, including a strong track record of building successful teams in early and growth-stage organizations while driving sales excellence and partner strategies. Mick will steer Virtuozzo’s global sales team executing the overall sales strategy, including expanding and improving its sales capabilities to support the growth of new customers and its core customer base – Virtuozzo’s network of 450+ service provider partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005288/en/
Mick’s appointment comes at a pivotal time for Virtuozzo as the Company accelerates growth in new and existing markets. Virtuozzo’s product portfolio is well suited to provide end-to-end cloud enablement for the fast-growing service provider market – both hosting service providers and the Company’s new vertical focus, managed and cloud service providers. Mick’s expertise and leadership will help drive the Company’s strategic vision and accelerate its growth, building upon over 21 years of innovation in the virtualization software business.
Previously Mick served as Senior Vice President & General Manager for EMEA at Arcserve, where he developed and implemented a strategy to move Arcserve from SMB into mid-markets and SME, resulting in significant revenue growth, channel expansion, and a successful transition to cloud service. Prior to this, he held several senior positions, including VP & General Manager for EMEA at Kaminario Inc., EMEA Managing Director at Violin Memory, Senior Director of EMEA Storage Consulting at Hewlett Packard, Chief Operating Officer at CopperEye, and Senior Vice President of Global Services at COPAN Systems.
“We’re thrilled to welcome Mick at such a critical time in Virtuozzo’s evolution. His extensive leadership and sales expertise will help establish Virtuozzo as the global leader in hybrid cloud enablement for the service provider market. Under Mick’s leadership, our sales team is well positioned to continue accelerating our business with a strong global team, solid solution portfolio, and a customer base of 450 service providers worldwide. With his expertise in growing both global and startup sales organizations in the software industry, Mick will bring our business to the next level. We couldn't be more excited," said Alex Fine, CEO, Virtuozzo.
“I’m joining Virtuozzo during an exciting time for both the Company and our partners and look forward to leveraging my experience to help both achieve massive growth. Virtuozzo’s ability to quickly offer cutting-edge cloud services is a game-changer for service providers seeking to differentiate and disrupt today. I am thrilled to be joining Virtuozzo and look forward to great things to come,” remarked Mick Bradley, VP of Global Sales, Virtuozzo.
About Virtuozzo
Virtuozzo is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel. Learn more https://go.virtuozzo.com/l/148051/2021-06-02/5kjhgs .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005288/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom